Document is current
Any future updates will be listed below
-
Authors
Krammer, Florian http://orcid.org/0000-0003-4121-776X
Schultz-Cherry, Stacey http://orcid.org/0000-0002-2021-727X
- License Information
-
More Information
Article History
First Online: 21 March 2023
Competing interests
: F.K. has been consulting for Curevac, Seqirus and Merck and is currently consulting for Pfizer, Third Rock Ventures, Avimex and GSK. He is named on several patents regarding influenza virus and SARS-CoV-2 vaccines, influenza virus therapeutics and SARS-CoV-2 serological tests. Some of these technologies have been licensed to commercial entities and F.K. is receiving royalties from these entities. F.K. is also an advisory board member of Castlevax, a spin-off company formed by the Icahn School of Medicine at Mount Sinai to develop SARS-CoV-2 vaccines. The Krammer laboratory has received funding for research projects from Pfizer, GSK and Dynavax and three of F.K.’s mentees have recently joined Moderna. S.S.-C. declares no competing interests.
Free to read: This content has been made available to all.
